Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Treatment, no treatment and early death in Danish stage I lung cancer patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Daniel Morgensztern
  • Nina Karaseva
  • Enriqueta Felip
  • Ignacio Delgado
  • Olga Burdaeva
  • Manuel Dómine
  • Primo Lara
  • Paul K Paik
  • Ulrik Lassen
  • Sergey Orlov
  • José Trigo
  • Marina Shomova
  • Katherine Baker-Neblett
  • James Vasquez
  • Xiaowei Wang
  • Li Yan
  • Ionel Mitrica
  • M Phillip DeYoung
  • Pilar Garrido
View graph of relations

OBJECTIVES: GSK3052230 (FP-1039) is a soluble fusion protein that acts as ligand trap sequestering fibroblast growth factors (FGFs) involved in tumor growth and angiogenesis, while sparing the hormonal FGFs. Because of this selectivity, the molecule is predicted to avoid toxicities associated with small molecule inhibitors of FGFR, including hyperphosphatemia and retinal, nail, and skin toxicities. Herein we report the results of a phase 1b study where GSK3052330 was administered with standard of care chemotherapy in FGFR1-amplified squamous non-small cell lung cancer (sqNSCLC) patients.

METHODS AND METHODS: Eligible patients with stage IV or recurrent metastatic sqNSCLC harboring FGFR1 gene amplification received escalating doses of GSK3052230 in combination with paclitaxel and carboplatin at the starting doses 200 mg/m2 and AUC of 6, respectively, in the first line setting (Arm A) or docetaxel 75 mg/m2 in second line (Arm B). The primary endpoints of the study were safety and tolerability, to identify a maximum tolerated dose (MTD), and to assess overall response rate (ORR) based on investigator assessment.

RESULTS: Twenty-nine patients were enrolled into the study, including 20 patients on Arm A and 9 patients on Arm B. There were no dose limiting toxicities in either Arm and the MTD was not reached. The most common adverse events (AEs) were compatible with the chemotherapy backbone used in each Arm, including neutropenia, alopecia, nausea, arthralgia, asthenia, diarrhea and peripheral neuropathy. The overall response rate and median progression-free survival were 47% and 5.5 months, respectively, for Arm A and 0% and 4.6 months, respectively, for Arm B.

CONCLUSION: GSK3052230 is a novel FGFR pathway inhibitor, which is well tolerated in combination with chemotherapy. Importantly, AEs associated with small molecule inhibitors of FGFR were not observed, as predicted by the unique mechanism of action of this drug.

Original languageEnglish
JournalLung cancer
Volume136
Pages (from-to)74-79
Number of pages6
ISSN0169-5002
DOIs
Publication statusPublished - Oct 2019

ID: 58970617